Clinical trials: Durvalumab
Part A and B: Advanced Solid Malignancies, Part C: Malignant Mesothelioma
Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, PK and Preliminary Anti-tumor Activity when given as a monotherapy of Tremelimumab or Tremelimumab in combination with MEDI4736 in Japanese Patients…
- Trial name
- NCT02141347
- Testing
- Tremelimumab, MEDI4736
- Where
- 11 sites in Japan
- Volunteers
- 65 people
- Sponsor
- AstraZeneca
Extensive-stage Small Cell Lung Cancer
SGI-110 Plus Durvalumab/Tremelimumab in SCLC
The purpose of this study is to determine if a combination of investigational agents is safe to give to people with small cell lung cancer (SCLC) after standard chemotherapy has been attempted.
- Trial name
- NCT03085849
- Testing
- Durvalumab, Tremelimumab, SGI-110
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Catherine Shu
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the combination regimen of daratumumab plus durvalumab (D2).
- Trial name
- FUSION-MM-005 (NCT03000452)
- Testing
- DARATUMUMAB, DURVALUMAB
- Where
- 25 sites in United States, Austria and 4 more
- Volunteers
- 18 people
- Sponsor
- Celgene
Solid Tumor, Adult
Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
A phase 1 study examining the combination of Durvalumab (MEDI4736) and Trabectedin in various solid tumor types. The study seeks to determine a safe dose of the combination of study drugs and then examine this dose in larger…
- Trial name
- NCT03496519
- Testing
- Dose Escalation of Durvalumab and Trabectedin, Dose Expansion of Durvalumab and Trabectedin
- Sponsor
- University of Colorado, Denver
EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma
Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL
PHASE II STUDY OF DURVALUMAB IN COMBINATION WITH LENALIDOMIDE IN RELAPSED/REFRACTORY EBV ASSOCIATED SUBTYPES OF DLBCL, PRIMARY CNS LYMPHOMA AND PRIMARY TESTICULAR DLBCL Patients with relapsed refractory subtypes of DLBCL who…
- Conditions
- EBV Related Non-Hodgkin's Lymphoma, Primary CNS Lymphoma, Primary Testicular Lymphoma
- Trial name
- DuRIANS (NCT03212807)
- Testing
- Durvalumab, Lenalidomide
- Where
- 4 sites in Singapore
- Sponsor
- Singapore General Hospital
Solitary Bone Plasmacytoma
A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma
This study is being done to evaluate whether the combination of immune therapy and radiation therapy to plasmacytoma that can stimulate the immune system to attack and eliminate the abnormal cells in the bone marrow and perhaps…
- Trial name
- NCT03196401
- Testing
- Durvalumab, Radiation therapy
- Where
- 6 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer, Primary Peritoneal Carcinoma
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
It is postulated that focal sensitizing radiotherapy may potentiate the effectiveness of durvalumab. The purpose of this study is to test the safety and tolerability of 2 different dose levels of focal sensitizing radiation…
- Conditions
- Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT03283943
- Testing
- Focal radiotherapy, Durvalumab
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- British Columbia Cancer Agency
Ovarian Clear Cell Carcinoma
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
The purpose of this study is to find out if treatment with a study drug, durvalumab has beneficial effects in people who have recurrent ovarian clear cell cancer and to determine what effects (both good and bad) it has on them…
- Trial name
- NCT03405454
- Testing
- durvalumab, standard chemotherapy
- Where
- 2 sites in Singapore
- Volunteers
- 46 people
- Sponsor
- National University Hospital, Singapore
Lymphoma, Large B-Cell, Diffuse
Durvalumab in DLBCL After Autologous Transplant
The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.
- Trial name
- IDA-D (NCT03241017)
- Testing
- Durvalumab
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if MEDI4736 given in combination with selumetinib can help to control advanced lung cancer. The safety of this drug combination will also be studied.
- Conditions
- Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma, Advanced Lung Cancer, Recurrent Nonsmall Cell Lung Cancer
- Trial name
- NCT03004105
- Testing
- Selumetinib, Durvalumab, Phone Calls
- Sponsor
- M.D. Anderson Cancer Center
Cutaneous T Cell Lymphoma
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
This is a single arm, single stage pilot study of radiation therapy plus durvalumab for tumor-stage cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT03235869
- Testing
- Durvalumab, Radiation Therapy
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer, Microsatellite Instability
- Trial name
- NCT02966587
- Testing
- Durvalumab, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Washington
Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
This is a Phase 1 Window of Opportunity study to evaluate the pharmacodynamic and immune effects of pre-operative therapy with Mocetinostat and Durvalumab on patients with squamous cell carcinoma of the oral cavity.
- Conditions
- Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth, Resectable Squamous Cell Carcinoma of Oral Cavity
- Trial name
- PRIMED-001 (NCT02993991)
- Testing
- Mocetinostat, Durvalumab
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Non-small Cell Lung Cancer
Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC
Despite aggressive surgery and chemotherapy, the risk of lung cancer recurrence remains high in most patients. This study aims to determine if a novel immune therapy consisting of two drugs is feasible and potentially increases…
- Trial name
- NCT03130764
- Testing
- Durvalumab, Tremelimumab
- Sponsor
- Columbia University
Head and Neck Neoplasms
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
In over 60% of cases, squamous cell carcinoma of the head and neck (SCCHN) is discovered at a loco-regionally advanced stage that requires a combined multimodal strategy in order to pursue a curative intent.
- Trial name
- DUCRO-HN (NCT03051906)
- Testing
- Durvalumab, Cetuximab, Intensity modulated radiation therapy (IMRT)
- Volunteers
- 69 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Squamous Cell Carcinoma of the Head and Neck
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab in…
- Trial name
- NCT02262741
- Testing
- MEDI4736, tremelimumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- MedImmune LLC
Bladder Cancer
Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer
This is a multi-site, randomized, prospective, open-label phase II study. Patients in this study will have localized (cT3-cT4), or metastatic bladder cancer with a symptomatic, intact primary bladder tumor.
- Trial name
- NCT03150836
- Testing
- Durvalumab, Tremelimumab, Radiation Therapy
- Where
- United States
- Sponsor
- Terence Friedlander, MD
Advanced Solid Tumors, Aggressive B-cell Lymphomas
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either…
- Trial name
- MEDI6469 (NCT02205333)
- Testing
- MEDI6469 Monotherapy, MEDI6469 Plus Tremelimumab, MEDI6469 Plus Durvalumab
- Where
- 13 sites in United States
- Volunteers
- 48 people
- Sponsor
- MedImmune LLC
LYMPHOMA
Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma
This is a multi-center, open-label, phase II study of durvalumab in combination with lenalidomide for treatment of relapsed/refractory NK/T-cell lymphoma (NKTCL).
- Trial name
- NCT03054532
- Testing
- Durvalumab, Lenali
- Where
- 4 sites in Singapore
- Volunteers
- 22 people
- Sponsor
- Singapore General Hospital